Polydopamine-Based Nanoparticles for Synergistic Chemotherapy of Prostate Cancer

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• The small molecule JQ1 inhibits the PD-L1 pathway, reversing doxorubicin (DOX)-induced PD-L1 upregulation.
• Synergistic administration of DOX and JQ1 can enhance anti-tumor immunity and sensitivity to immune checkpoint therapy.

Purpose of the Study:

• To develop a drug delivery system for synergistic prostate cancer therapy using DOX and JQ1.
• To evaluate the efficacy and biosafety of the drug delivery system in vitro and in vivo.

Main Methods:

• Polydopamine nanoparticles (PDA NPs) were synthesized and loaded with DOX and JQ1.
• In vitro studies included cell uptake, viability, apoptosis assays, and Western blot analysis.
• In vivo studies utilized a tumor-bearing mouse model to assess tumor inhibition and biosafety.

Main Results:

• PDA-DOX/JQ1 NPs successfully loaded both drugs and inhibited prostate cancer cell growth in vitro.
• In vivo studies showed PDA-DOX/JQ1 NPs accumulated at tumor sites, reduced PD-L1 expression, and significantly suppressed tumor growth.
• The nanoparticle system demonstrated reduced side effects and a synergistic therapeutic effect.

Conclusions:

• A multifunctional platform for synergistic prostate cancer therapy was successfully developed.
• PDA-DOX/JQ1 NPs offer a promising strategy for enhancing cancer treatment efficacy and reducing side effects.